JP7760500B2 - 生成物関連不純物を除去するためのカチオン交換クロマトグラフィー中の高塩分負荷コンディショニング - Google Patents

生成物関連不純物を除去するためのカチオン交換クロマトグラフィー中の高塩分負荷コンディショニング

Info

Publication number
JP7760500B2
JP7760500B2 JP2022525306A JP2022525306A JP7760500B2 JP 7760500 B2 JP7760500 B2 JP 7760500B2 JP 2022525306 A JP2022525306 A JP 2022525306A JP 2022525306 A JP2022525306 A JP 2022525306A JP 7760500 B2 JP7760500 B2 JP 7760500B2
Authority
JP
Japan
Prior art keywords
sodium chloride
acetate
buffer comprises
wash buffer
cation exchange
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022525306A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022554282A (ja
JP2022554282A5 (https=
Inventor
ディアス，ルイス
ゴメス，ナタリア
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2022554282A publication Critical patent/JP2022554282A/ja
Publication of JP2022554282A5 publication Critical patent/JP2022554282A5/ja
Priority to JP2025172458A priority Critical patent/JP2026012744A/ja
Application granted granted Critical
Publication of JP7760500B2 publication Critical patent/JP7760500B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2022525306A 2019-11-07 2020-11-04 生成物関連不純物を除去するためのカチオン交換クロマトグラフィー中の高塩分負荷コンディショニング Active JP7760500B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025172458A JP2026012744A (ja) 2019-11-07 2025-10-14 生成物関連不純物を除去するためのカチオン交換クロマトグラフィー中の高塩分負荷コンディショニング

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962931863P 2019-11-07 2019-11-07
US62/931,863 2019-11-07
PCT/US2020/058772 WO2021091932A1 (en) 2019-11-07 2020-11-04 High salt load conditioning during cation exchange chromatography to remove product-realated impurities

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025172458A Division JP2026012744A (ja) 2019-11-07 2025-10-14 生成物関連不純物を除去するためのカチオン交換クロマトグラフィー中の高塩分負荷コンディショニング

Publications (3)

Publication Number Publication Date
JP2022554282A JP2022554282A (ja) 2022-12-28
JP2022554282A5 JP2022554282A5 (https=) 2023-08-15
JP7760500B2 true JP7760500B2 (ja) 2025-10-27

Family

ID=73598211

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022525306A Active JP7760500B2 (ja) 2019-11-07 2020-11-04 生成物関連不純物を除去するためのカチオン交換クロマトグラフィー中の高塩分負荷コンディショニング
JP2025172458A Pending JP2026012744A (ja) 2019-11-07 2025-10-14 生成物関連不純物を除去するためのカチオン交換クロマトグラフィー中の高塩分負荷コンディショニング

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025172458A Pending JP2026012744A (ja) 2019-11-07 2025-10-14 生成物関連不純物を除去するためのカチオン交換クロマトグラフィー中の高塩分負荷コンディショニング

Country Status (13)

Country Link
US (1) US20220372070A1 (https=)
EP (1) EP4055041A1 (https=)
JP (2) JP7760500B2 (https=)
KR (1) KR20220092969A (https=)
CN (1) CN114746441A (https=)
AU (1) AU2020380256A1 (https=)
BR (1) BR112022008649A2 (https=)
CA (1) CA3160143A1 (https=)
CL (3) CL2022001168A1 (https=)
IL (1) IL292594A (https=)
MX (1) MX2022005593A (https=)
WO (1) WO2021091932A1 (https=)
ZA (1) ZA202205010B (https=)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009530378A (ja) 2006-03-20 2009-08-27 メダレックス インコーポレーティッド タンパク質精製法
JP2013078313A (ja) 2006-03-31 2013-05-02 Chugai Pharmaceut Co Ltd 二重特異性抗体を精製するための抗体改変方法
US20160145339A1 (en) 2014-07-21 2016-05-26 Wuhan Yzy Biopharma Co., Ltd. Construction and application of bispecific antibody HER2xCD3
JP2016183113A (ja) 2015-03-25 2016-10-20 東ソー株式会社 Ｆｃ結合性タンパク質の精製方法
WO2019088143A1 (ja) 2017-11-01 2019-05-09 中外製薬株式会社 生物活性が低下した抗体バリアントおよびアイソフォーム

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019970A2 (en) * 1999-09-15 2001-03-22 Eli Lilly And Company Chymotrypsin-free trypsin
CN104628846B (zh) * 2013-11-06 2019-12-06 三生国健药业（上海）股份有限公司 重组蛋白质的纯化方法
EP3204415B1 (en) * 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
CN110305217B (zh) * 2018-03-27 2022-03-29 广州爱思迈生物医药科技有限公司 双特异性抗体及其应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009530378A (ja) 2006-03-20 2009-08-27 メダレックス インコーポレーティッド タンパク質精製法
JP2013078313A (ja) 2006-03-31 2013-05-02 Chugai Pharmaceut Co Ltd 二重特異性抗体を精製するための抗体改変方法
US20160145339A1 (en) 2014-07-21 2016-05-26 Wuhan Yzy Biopharma Co., Ltd. Construction and application of bispecific antibody HER2xCD3
JP2016183113A (ja) 2015-03-25 2016-10-20 東ソー株式会社 Ｆｃ結合性タンパク質の精製方法
WO2019088143A1 (ja) 2017-11-01 2019-05-09 中外製薬株式会社 生物活性が低下した抗体バリアントおよびアイソフォーム

Also Published As

Publication number Publication date
CL2022001168A1 (es) 2023-01-27
EP4055041A1 (en) 2022-09-14
MX2022005593A (es) 2022-06-09
WO2021091932A1 (en) 2021-05-14
CL2024001788A1 (es) 2024-09-27
JP2022554282A (ja) 2022-12-28
AU2020380256A1 (en) 2022-06-09
CL2025003712A1 (es) 2026-01-09
IL292594A (en) 2022-07-01
KR20220092969A (ko) 2022-07-04
CN114746441A (zh) 2022-07-12
BR112022008649A2 (pt) 2022-07-19
CA3160143A1 (en) 2021-05-14
US20220372070A1 (en) 2022-11-24
ZA202205010B (en) 2023-01-25
JP2026012744A (ja) 2026-01-27

Similar Documents

Publication Publication Date Title
US20220119526A1 (en) A continuous manufacturing process for biologics manufacturing by integration of drug substance and drug product processes
WO2022072291A1 (en) Cation exchange chromatography process
US20230058276A1 (en) Methods for harvesting biomolecules
JP2026048656A (ja) 生成物関連不純物を除去するためのカチオン交換クロマトグラフィー中の高塩分洗浄
US20240174752A1 (en) Modulating product quality of asymmetric multispecific antibodies through the use of temperature
JP7760500B2 (ja) 生成物関連不純物を除去するためのカチオン交換クロマトグラフィー中の高塩分負荷コンディショニング
US20260070943A1 (en) A method for harvesting products from high cell density perfusion cell cultures
EA047099B1 (ru) Кондиционирование с высокой солевой нагрузкой в ходе катионообменной хроматографии для удаления связанных с продуктом примесей
EA046702B1 (ru) Способы очистки биспецифических антител при помощи катионообменной хроматографии с использованием промывки с высоким содержанием соли
HK40070045A (en) High salt load conditioning during cation exchange chromatography to remove product-realated impurities
HK40070589A (en) High salt washes during cation exchange chromatography to remove product-realated impurities
WO2025251034A1 (en) Purification method
JP2026505293A (ja) 細胞培養法
EA052848B1 (ru) Способ осуществления сбора продуктов из перфузионных культур
EA049616B1 (ru) Непрерывный способ изготовления биопрепаратов посредством интеграции процессов получения лекарственного вещества и лекарственного препарата

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230804

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230804

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250714

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250916

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251015

R150 Certificate of patent or registration of utility model

Ref document number: 7760500

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150